Press coverage about Aradigm Corporation (NASDAQ:ARDM) has been trending somewhat positive on Wednesday, according to Accern. Accern rates the sentiment of news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Aradigm Corporation earned a news sentiment score of 0.16 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 46.441447805008 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Aradigm Corporation (ARDM) opened at 1.40 on Wednesday. Aradigm Corporation has a one year low of $0.78 and a one year high of $7.19. The firm’s market capitalization is $20.20 million. The company has a 50-day moving average of $1.32 and a 200 day moving average of $1.39.
Aradigm Corporation (NASDAQ:ARDM) last issued its quarterly earnings results on Thursday, August 10th. The company reported $0.07 earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.30) by $0.37. The company had revenue of $7.68 million for the quarter. Aradigm Corporation had a negative net margin of 196.65% and a negative return on equity of 665.03%. On average, analysts anticipate that Aradigm Corporation will post ($0.74) EPS for the current year.
Separately, Zacks Investment Research upgraded shares of Aradigm Corporation from a “hold” rating to a “buy” rating and set a $1.50 price objective on the stock in a report on Tuesday, August 22nd.
TRADEMARK VIOLATION NOTICE: This report was reported by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this report on another site, it was copied illegally and republished in violation of United States and international copyright legislation. The legal version of this report can be viewed at https://stocknewstimes.com/2017/09/20/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-aradigm-corporation-ardm-stock-price.html.
Aradigm Corporation Company Profile
Aradigm Corporation is a pharmaceutical company focused on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. The Company’s lead product candidate is Pulmaquin inhaled ciprofloxacin, which is in Phase III clinical trials. It offers AERx pulmonary drug delivery platform and other technologies.
Receive News & Ratings for Aradigm Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aradigm Corporation and related companies with MarketBeat.com's FREE daily email newsletter.